---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-071400"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2023-03-15T23:59:59+00:00"
generated_at: "2026-06-18T02:09:27.410944+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics enters $75M at-the-market stock offering agreement with Jefferies

## Summary
- Company entered Open Market Sale Agreement with Jefferies LLC to sell up to $75M of common stock.
- Sales will be made 'at the market' under existing shelf registration statement (File No. 333-261019).
- Jefferies receives up to 3.0% commission on gross proceeds; company not obligated to sell any shares.
- Agreement terminates upon sale of all shares or earlier termination by either party.
- Proceeds intended for general corporate purposes and working capital.

## SEC filing metadata
- accession: 0001193125-23-071400
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2023-03-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312523071400/0001193125-23-071400-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312523071400/d405925d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-071400
- JSON: https://secwatch.observer/filing/0001193125-23-071400.json
- Plain text: https://secwatch.observer/filing/0001193125-23-071400.txt

## Key facts
- Material Agreements
  Prelude Therapeutics Inc entered into Sales Agreement with Jefferies LLC valued at up to $75.0 million (effective 2023-03-15).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: up to $75.0 million
  - Effective: 2023-03-15
  source text: On March 15, 2023, Prelude Therapeutics Incorporated (the “Company”), entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC, as sales agent and/or principal (“Jefferies”), pursuant to which the Company may offer and sell, from time to time to or through Jefferies, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $75.0 million (the “Shares”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1678660/000119312523071400/0001193125-23-071400-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.